Store Research
ASSEMBLY BILL 1113 (ROGAN – 1995)
CHAPTER 455, STATUTES OF 1995, AB 1113
Some bill research does not include the Governor's file because at the time we researched the bill, the sitting Governor had not released his chaptered bill file. If the Governor's file is not included with this particular research, please contact our office (1-530-666-1917 or quote@legintent.com) and we will be happy to provide this file at no charge if it is available. Please Note: Governor files did not exist prior to 1943.
As enacted Assembly Bill 113 amended sections in the Family Code, Harbor and Navigation Code, Health and Safety, Vehicle Code, and Welfare and Institutions Code relating to controlled substances. (See Exhibit #1g) Assembly member Rogan introduced the bill on February 23, 1995 at the request of Forest Tenant, from the Community Health Projects Medical Group. (See Exhibits #1a and #3, page 3)
Assembly Bill 1113 was assigned to the Assembly Committee on Public Safety and the Senate Committee on Criminal Procedure where policy issues raised by the bill were considered. (See Exhibits #3 and #8) The fiscal ramifications of the bill were considered by the Assembly Committee on Appropriations and the Assembly Committee on Appropriations. (See Exhibits #5 and #2) Five amendments were made to Assembly Bill 1113 during the legislative process. (See Exhibits #1b through #1f and #2) Subsequent to legislative approval, Governor Pete Wilson signed the bill on September 2, 1995 and it was recorded by the Secretary of State on September 5th as Chapter 455 of the Statutes of 1995. (See Exhibits #1g and #2)
The Third Reading analysis prepared by the Office of Senate Floor Analyses provides the following digest of Assembly Bill 1113:
DIGEST: This bill provides that levoalphacetylmethadol (LAAM) be transferred from the Schedule I to the Schedule II controlled substance list.
This bill also provides that LASM be made available for the treatment of heroin addiction.
Senate Floor Amendments of 7/15/95 added clarifying language.
(See Exhibit #11b, page 1)